Citadel Advisors’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.66M | Buy |
759,000
+151,400
| +25% | +$484K | ﹤0.01% | 5498 |
|
|
2025
Q4 | $1.66M | Buy |
607,600
+24,500
| +4% | +$56.7K | ﹤0.01% | 6294 |
|
|
2025
Q3 | $1.27M | Buy |
583,100
+153,700
| +36% | +$363K | ﹤0.01% | 7032 |
|
|
2025
Q2 | $739K | Buy |
429,400
+128,300
| +43% | +$319K | ﹤0.01% | 7732 |
|
|
2025
Q1 | $1M | Sell |
301,100
-131,800
| -30% | -$680K | ﹤0.01% | 6949 |
|
|
2024
Q4 | $3.2M | Buy |
432,900
+105,300
| +32% | +$976K | ﹤0.01% | 4736 |
|
|
2024
Q3 | $3.08M | Buy |
327,600
+15,900
| +5% | +$151K | ﹤0.01% | 4733 |
|
|
2024
Q2 | $2.5M | Sell |
311,700
-297,500
| -49% | -$3.19M | ﹤0.01% | 4904 |
|
|
2024
Q1 | $9.03M | Buy |
609,200
+268,900
| +79% | +$3.13M | ﹤0.01% | 3068 |
|
|
2023
Q4 | $2.77M | Sell |
340,300
-12,600
| -4% | -$65.9K | ﹤0.01% | 4790 |
|
|
2023
Q3 | $1.61M | Buy |
352,900
+59,400
| +20% | +$388K | ﹤0.01% | 5623 |
|
|
2023
Q2 | $2.07M | Sell |
293,500
-30,900
| -10% | -$221K | ﹤0.01% | 5091 |
|
|
2023
Q1 | $1.98M | Buy |
324,400
+152,200
| +88% | +$1.05M | ﹤0.01% | 5388 |
|
|
2022
Q4 | $1.1M | Sell |
172,200
-33,800
| -16% | -$264K | ﹤0.01% | 6631 |
|
|
2022
Q3 | $1.97M | Sell |
206,000
-70,300
| -25% | -$811K | ﹤0.01% | 5619 |
|
|
2022
Q2 | $3.05M | Sell |
276,300
-160,800
| -37% | -$2.11M | ﹤0.01% | 4729 |
|
|
2022
Q1 | $7.28M | Buy |
437,100
+193,000
| +79% | +$2.98M | ﹤0.01% | 3484 |
|
|
2021
Q4 | $4.66M | Buy |
244,100
+16,900
| +7% | +$372K | ﹤0.01% | 4432 |
|
|
2021
Q3 | $5.6M | Buy |
227,200
+29,100
| +15% | +$686K | ﹤0.01% | 4095 |
|
|
2021
Q2 | $5.16M | Buy |
198,100
+62,200
| +46% | +$1.62M | ﹤0.01% | 4355 |
|
|
2021
Q1 | $4.3M | Sell |
135,900
-98,200
| -42% | -$4.07M | ﹤0.01% | 4605 |
|
|
2020
Q4 | $10.9M | Buy |
234,100
+134,400
| +135% | +$5.34M | ﹤0.01% | 2541 |
|
|
2020
Q3 | $3.28M | Sell |
99,700
-73,300
| -42% | -$2.25M | ﹤0.01% | 3836 |
|
|
2020
Q2 | $4.75M | Buy |
173,000
+52,300
| +43% | +$1.72M | ﹤0.01% | 3160 |
|
|
2020
Q1 | $3.61M | Sell |
120,700
-99,100
| -45% | -$2.63M | ﹤0.01% | 3177 |
|
|
2019
Q4 | $6.08M | Sell |
219,800
-185,500
| -46% | -$4.22M | ﹤0.01% | 2837 |
|
|
2019
Q3 | $7.38M | Buy |
405,300
+146,700
| +57% | +$3.24M | ﹤0.01% | 2594 |
|
|
2019
Q2 | $6.34M | Buy |
+258,600
| New | +$3.9M | ﹤0.01% | 2757 |
|
|
2019
Q1 | – | Sell |
-18,400
| Closed | -$163K | – | 9567 |
|
|
2018
Q4 | $163K | Sell |
18,400
-33,700
| -65% | -$325K | ﹤0.01% | 8008 |
|
|
2018
Q3 | $586K | Buy |
52,100
+24,100
| +86% | +$342K | ﹤0.01% | 6444 |
|
|
2018
Q2 | $358K | Sell |
28,000
-300
| -1% | -$4.38K | ﹤0.01% | 6919 |
|
|
2018
Q1 | $478K | Buy |
28,300
+17,100
| +153% | +$259K | ﹤0.01% | 5952 |
|
|
2017
Q4 | $90K | Buy |
+11,200
| New | +$89.9K | ﹤0.01% | 7466 |
|
|
2017
Q1 | – | Sell |
-10,000
| Closed | -$70K | – | 7740 |
|
|
2016
Q4 | $70K | Sell |
10,000
-3,100
| -24% | -$21.3K | ﹤0.01% | 6788 |
|
|
2016
Q3 | $108K | Buy |
+13,100
| New | +$111K | ﹤0.01% | 6626 |
|
|
2016
Q2 | – | Sell |
-40,300
| Closed | -$205K | – | 7077 |
|
|
2016
Q1 | $205K | Buy |
40,300
+26,700
| +196% | +$146K | ﹤0.01% | 5609 |
|
|
2015
Q4 | $105K | Buy |
+13,600
| New | +$94.4K | ﹤0.01% | 6622 |
|
|
2015
Q3 | – | Sell |
-800
| Closed | -$7K | – | 9050 |
|
|
2015
Q2 | $7K | Buy |
+800
| New | +$8.93K | ﹤0.01% | 8475 |
|
Other funds holding IOVA
MFM
VCM
VPM
ICM
Citadel Advisors's IOVA Position: Q1 2026 in Review
Citadel Advisors reduced its Iovance Biotherapeutics (IOVA) stake by 17% in Q1 2026, selling an estimated $1.7M and leaving 2,611,345 shares worth $9.17M. The position accounts for ﹤0.01% of the portfolio, ranked #3375.
Citadel Advisors first reported a position in IOVA in Q2 2015 and has held it in 42 quarters since. The position peaked at $61.9M in Q2 2021. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.
- Citadel Advisors held 2,611,345 shares of Iovance Biotherapeutics worth $9.17M as of Q1 2026.
- Citadel Advisors sold 531,746 Iovance Biotherapeutics shares in Q1 2026, an estimated $1.7M.
- Iovance Biotherapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3375 holding.
- Citadel Advisors first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 42 quarters since.
- Citadel Advisors's Iovance Biotherapeutics position peaked at $61.9M in Q2 2021.
- 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.